Navigation Links
Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
Date:2/20/2008

TAMPA, Fla., Feb. 20 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that it has entered into an exclusive licensing agreement with Bridge Pharma, Inc. of Sarasota, FL for the worldwide rights to develop and market topical ophthalmic formulations containing Bridge Pharma's proprietary anti- inflammatory agent norketotifen.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

"This agreement represents yet another significant milestone for Sirion. We are very excited about the medical and market potential of the norketotifen molecule," said Roger Vogel, MD, Chief Medical Officer of Sirion Therapeutics.

Under the terms of this licensing agreement, Sirion Therapeutics will have the rights to manufacture, sell and distribute norketotifen for ocular use either alone or in combination with other drugs. Norketotifen is a potent anti-inflammatory drug with additional antihistaminic activity that may have clinical utility in various ocular conditions.

"We hope to begin clinical trials with the new formulation of norketotifen in the first half of 2009," said Barry Butler, Chief Executive Officer of Sirion Therapeutics.

Dr. Gunnar Aberg, Chief Executive Officer of Bridge Pharma, said, "We are pleased to be working with Sirion Therapeutics, a company that has made impressive strides since its founding and is staffed with highly qualified individuals with many years of experience in developing and launching ophthalmic pharmaceuticals."

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's pipeline includes four compounds: difluprednate, a topical steroid for post- operative inflammation and uveitis; ganciclovir, a topical antiviral for herpetic keratitis; cyclosporine, a topical immunomodulator for dry eye; and fenretinide, a first-in-class oral vitamin A binding protein antagonist for geographic atrophy associated with dry AMD. In addition, Sirion has preclinical programs in back of the eye diseases and allergy. For more information, please visit http://www.siriontherapeutics.com .

About Bridge Pharma, Inc.

Bridge Pharma, Inc. is a privately held pharmaceutical research and development company located in Sarasota, FL. Bridge Pharma was founded in 1996 by Dr. Gunnar Aberg, currently CEO. In addition to the current license with Sirion Therapeutics, Bridge has out-licensed internally developed drugs for growth promotion, heaves in horses, obesity, pain, over-active bladder and urinary incontinence. Bridge is committed to the discovery, research and development of NCEs that provide therapeutic treatment for unmet medical needs.

Forward-Looking Statements

This press release contains forward-looking statements and information about Sirion Therapeutics, Inc.'s and Bridge Pharma Inc.'s business and products. These forward-looking statements are only business forecasts. Actual results may differ from the results anticipated, expressed or implied by these forward-looking statements and are dependent upon, among other things, drug applications and regulatory authorizations.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Ocera Therapeutics Closes $35.5 Million Series C Financing
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
4. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
5. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
6. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
7. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
8. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
11. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
Breaking Biology News(10 mins):